Evaluating the effects of 14‐day oral vedaprofen and tolfenamic acid treatment on renal function, hematological and biochemical profiles in healthy cats

Abstract

The objective of this study was to evaluate the effects of the nonsteroidal anti-inflammatory drugs vedaprofen and tolfenamic acid on renal function after oral administration for 2 weeks in healthy cats. Experiments were performed using nineteen domestic short-haired cats randomly divided into one control (n=6) and two treatment groups. All cats in the first (n=6) and second treatment groups (n=7) received vedaprofen (0.5 mg/kg/day) and tolfenamic acid (4 mg/kg/day), respectively. During the experiment, renal function was evaluated using percent renal uptakes of (99m)Technetium-diethylenetriamine-pentaacetic acid ((99m)Tc-DTPA) collected from renal scintigraphy and blood samples used to determine complete blood count and biochemical profiles. Renal scintigraphy and blood collections were performed at days 0, 5, 11, 15, and 45. The percent of renal uptake after the administration of vedaprofen and tolfenamic acid were not significantly different compared to pretreatment (day 0) and control group levels. In addition, significant changes were not observed in hematological and biochemical profiles within or between groups, with the exception of slightly lower numbers in red blood cell counts compared to the normal value on day 45 in the tolfenamic acid-treated group. Taken together, we conclude 14-day administration of vedaprofen and tolfenamic acid might not cause any adverse effects on renal function, hematological and serum biochemical variables.

Comparison of post-operative analgesic efficacy of tolfenamic acid and robenacoxib in ovariohysterectomized cats

“…The effects of tolfenamic acid and robenacoxib in cats with bleeding disorders are beyond the scope of the present study. Similar to our study, previous research has found that tolfenamic acid [ 12 ] and robenacoxib [ 13 ] have no effect on renal function, hematological profiles, or biochemical profiles in healthy cats. Nonetheless, care should be taken to administer NSAIDs to cats with thrombocytopenia or anemia, or to those receiving anticoagulants, as NSAIDs may prolong coagulation time.…”

“…Tolfenamic acid is among the conventional non-selective COX inhibitors commonly used in Thailand [ 12 ]. Non-selective NSAIDs inhibit both COX-1 and COX-2, leading to reduce inflammation due to the inhibition of prostaglandin production [ 20 , 30 ].…”

“…Tolfenamic acid is a commonly used nonselective COX inhibitor in cats [ 12 ]. It has a COX-1/COX-2 ratio of 16 in dogs [ 22 ], but the COX-1/COX-2 ratio of tolfenamic acid in cats has not been reported.…”

“…Robenacoxib is a selective COX-2 inhibitor with a COX-1/COX-2 ratio of 66.9 to 171 in cats [ 10 , 11 , 13 , 17 , 24 , 25 ]. Several studies have evaluated the efficacy of tolfenamic acid and robenacoxib [ 4 , 11 , 12 , 24 , 25 , 27 , 29 ]. However, studies have not compared the efficacy of tolfenamic acid and robenacoxib in cats.…”

Cyclooxygenase-2 expression in epithelial neoplasms and its relevance as a targeted therapy in dogs

“…NSAIDs act mainly through the inhibition of COX activity in the biochemical cascade that leads to prostaglandin synthesis, and there are selective NSAIDs for COX-2 inhibition (KHWANJAI et al, 2011). COX-1 and COX-2 are involved in renal blood flow and tubular function regulation; therefore, selective COX-2 NSAIDs do not necessarily cause less renal side effects.…”